Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Biofrontera FY 2024 GAAP EPS $(3.22) May Not Be Comparable To $(0.85) Estimate, Sales $37.32M Miss $47.06M Estimate

Author: Benzinga Newsdesk | March 21, 2025 06:25am
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(3.22) per share which missed the analyst consensus estimate of $(0.85) by 278.82 percent. This is a 75.27 percent increase over losses of $(13.02) per share from the same period last year. The company reported quarterly sales of $37.32 million which missed the analyst consensus estimate of $47.06 million by 20.69 percent. This is a 9.54 percent increase over sales of $34.07 million the same period last year.

Posted In: BFRI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist